A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. [electronic resource]
Producer: 20101227Description: 429-38 p. digitalISSN:- 1365-2710
- Angiogenesis Inhibitors -- administration & dosage
- Carcinoma, Renal Cell -- drug therapy
- Cost-Benefit Analysis
- Cytokines -- therapeutic use
- Disease Progression
- Disease-Free Survival
- Drug Costs
- Drug Resistance, Neoplasm
- Female
- Health Care Costs
- Humans
- Immunotherapy
- Indoles -- administration & dosage
- Kidney Neoplasms -- drug therapy
- Male
- Markov Chains
- Middle Aged
- Models, Economic
- Palliative Care -- economics
- Protein Kinase Inhibitors -- administration & dosage
- Pyrroles -- administration & dosage
- Quality-Adjusted Life Years
- Spain
- Sunitinib
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.